Following their review of updates from clinical trials presented at ASH 2023, the Oncology Brothers provide their key takeaways on recent data in myelofibrosis and acute myeloid leukemia.
FDA Enforces Partial Hold on Trial of Seclidemstat in MDS/CMML
July 16th 2024Following the report of a serious and unexpected grade 4 adverse effect, a partial clinical hold has been placed on the phase 1 trial evaluating seclidemstat with azacitidine in myelodysplastic syndrome and chronic myelomonocytic leukemia.
Read More